Prexasertib (LY2606368) reduces clonogenic survival by inducing apoptosis in primary patient‐derived osteosarcoma cells and synergizes with cisplatin and talazoparib

Progress in the systemic control of osteosarcoma has been limited over the past decades thus indicating the urgent clinical need for the development of novel treatment strategies. Therefore, we have recently developed new preclinical models to study promising novel agents for the treatment of pediat...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Int J Cancer
Autors principals: Heidler, Christopher L., Roth, Eva K., Thiemann, Markus, Blattmann, Claudia, Perez, Ramon L., Huber, Peter E., Kovac, Michal, Amthor, Beate, Neu‐Yilik, Gabriele, Kulozik, Andreas E.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons, Inc. 2019
Matèries:
Cancer Therapy and Prevention
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7384073/
https://ncbi.nlm.nih.gov/pubmed/31782150
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.32814
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars